Compare YDKG & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YDKG | MBIO |
|---|---|---|
| Founded | 2005 | 2015 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9M | 4.7M |
| IPO Year | N/A | N/A |
| Metric | YDKG | MBIO |
|---|---|---|
| Price | $1.04 | $1.07 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 140.0K | 75.1K |
| Earning Date | 03-06-2026 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $13,107,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 2175.52 | N/A |
| 52 Week Low | $0.81 | $0.89 |
| 52 Week High | $669.00 | $7.00 |
| Indicator | YDKG | MBIO |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 43.96 |
| Support Level | N/A | $1.07 |
| Resistance Level | N/A | $1.20 |
| Average True Range (ATR) | 0.00 | 0.06 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 0.00 | 50.00 |
Yueda Digital Holding is a digital-economy company with a focus on the long-term accumulation of mainstream cryptocurrencies. The business activities of the company include active treasury management of mainstream digital assets, exploration of compliant, risk-managed yield opportunities, such as staking, on-chain liquidity provision, and other conservative market activities, selective investments and partnerships in Web3 infrastructure and applications, and advisory services for enterprises entering the digital-asset economy.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.